Engflag

Pantogram

Quick links to important sections

Pantogram

Pantogram_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pantogram

Understanding Pantogram

Pantogram is a pharmacological agent that belongs to the class of nootropics, also known as neurometabolic stimulants. It is a derivative of gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the central nervous system. Specifically, it consists of the calcium salt of hopantenic acid.

Mechanism and Characteristics

The structure of the active substance is designed to facilitate its interaction with GABA receptors. Unlike pure GABA, which has difficulty crossing the blood-brain barrier, the modified structure of hopantenic acid allows for better penetration into brain tissues. Once active, it influences the metabolic processes within neurons and modulates neurotransmission.

Its action is characterized by a combination of mild sedative properties and stimulating effects on cognitive functions. It is typically used to support the brain's resilience to hypoxia (oxygen deprivation) and the effects of toxic substances.

General Properties

  • Neuroprotective effect: It aims to protect neurons from various forms of metabolic stress.
  • Cognitive support: It is used in contexts where improvement in memory, attention, and learning capacity is required.
  • Anticonvulsant activity: It may help in reducing excessive neuronal excitability.
  • Metabolic regulation: It assists in normalizing the exchange of glucose and oxygen in the brain tissues.

Common Applications

In clinical practice, Pantogram is utilized across different age groups for various neurological and developmental conditions. In pediatric care, it is often associated with the management of developmental delays or hyperkinetic disorders. In adults, it is frequently used to address cognitive impairment resulting from organic brain lesions, cerebrovascular insufficiency, or physical and emotional overexertion.

Regulatory References

  1. Erythromycin: MedlinePlus Drug Information
  2. WHO Essential Medicines Lists

What side effects are possible with Pantogram?

Possible Side Effects and Safety Information

The safety profile of Pantogram (erythromycin) is characterized by a spectrum of adverse reactions classified by frequency and categorized by the organ system affected, as documented in regulatory sources.

Adverse Reaction Scope

The most commonly reported adverse effects are generally related to the gastrointestinal system, including nausea, vomiting, abdominal pain, and diarrhea. These effects are often noted to be dose-related in regulatory labeling. Uncommon reactions include hypersensitivity manifestations like rash and urticaria.

Serious Adverse Reactions

Official documents specifically list the risk of developing life-threatening ventricular arrhythmias, such as Torsades de Pointes, particularly when the medicine is used by patients with pre-existing cardiac conditions. Other serious risks include signs of hepatotoxicity (e.g., cholestatic hepatitis) and severe cutaneous adverse reactions (SCARs). Additionally, Pseudomembranous Colitis (C. difficile-associated diarrhea) is a documented, serious gastrointestinal complication that may occur during or following antibacterial therapy.

Key Safety Constraints and Considerations

The medicine is officially contraindicated in patients with a known history of macrolide hypersensitivity or pre-existing conditions like QT prolongation or ventricular cardiac arrhythmia. Regulatory safety information notes a specific association between erythromycin administration in newborns/infants and the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). For patients with impaired liver function, the risk of hepatic adverse reactions is also heightened, a factor explicitly addressed in the official safety profile.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented manifestations of overdosage and the corresponding mandated emergency actions, as established by governmental regulatory authorities for Pantogram (Erythromycin).

Documented Overdose Profile

Domain Official Regulatory Statement
Overdose Presentations Overdosage may be associated with symptoms including nausea, vomiting, diarrhea, and abdominal cramps
Life-Threatening Risks Potential for severe cardiac disturbances (such as QT interval prolongation, Torsades de pointes, and Ventricular Arrhythmias) and severe hepatic dysfunction (including liver injury)
Emergency Intervention Overdosage requires the discontinuation of the drug, along with the prompt elimination of unabsorbed drug and the institution of general supportive measures
Management Note The drug is not removed by hemodialysis or peritoneal dialysis

When to Seek Urgent Help

Regulatory documentation mandates that any suspected overdosage requires immediate action. Patients must seek emergency medical attention or contact a poison control center at once for guidance. This urgent care requirement is due to the potential for the overexposure event to lead to documented, life-threatening outcomes, particularly severe cardiac arrhythmias, which necessitate expert medical assessment.

Therapeutic Uses of Pantogram

What Pantogram treats: main uses and benefits

Pantogram is an oral macrolide antibiotic generally applied in clinical settings that involve acute or disruptive symptom patterns caused by susceptible bacteria. It is considered a relevant therapeutic choice for patients who are unable to use penicillin due to allergy, and is commonly used to help with long-term prophylaxis against conditions like rheumatic fever. The medication is relevant in contexts marked by increased discomfort or tension to address conditions presenting with heightened symptoms, such as bronchitis, pneumonia, acute otitis media, and skin and soft tissue infections. It is considered relevant for managing specific sexually transmitted infections like Chlamydial infections and Primary Syphilis.

Quick Fact: Supportive Symptom Management

Property Description
Therapeutic Scope Applied across domains where additional symptomatic support is needed
Symptom Relevance Helps address symptom clusters that may become intense or disruptive
Use Context Relevant when supportive symptom management is appropriate in acute episodes

This provides supportive relief when symptoms interfere with routine activities, and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Absolute Contraindications

Use of Pantogram (Erythromycin) is strictly contraindicated for several populations as documented in official regulatory labeling. This includes individuals with a known hypersensitivity to Pantogram or any macrolide antibiotic. It is also prohibited for patients with a documented history of QT prolongation or ventricular cardiac arrhythmia. Concomitant use with specific medications such as Ergotamine or Dihydroergotamine and certain HMG-CoA reductase inhibitors (like Lovastatin) is absolutely prohibited to prevent severe adverse outcomes.

Conditional Use and Restrictions

Use requires caution and close monitoring in patients with impaired hepatic function, as the liver is the primary route of excretion. Caution is also necessary for those with Myasthenia Gravis due to reported aggravation of weakness, and in cases of severe renal impairment, which may necessitate a mandatory dose limitation.

Age and Developmental Status

Use is generally established for adults and children; however, the tablet form is not recommended for children under 8 years. Use in infants requires careful monitoring due to the potential risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). The medication is excreted in human milk requiring caution during lactation, and use for syphilis during pregnancy requires mandatory infant follow-up treatment.

What should I know about interactions with other medicines?

Pantogram Interactions with other medicines and products

The official interaction profile for Pantogram (Erythromycin) is defined primarily by its role as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme system. This pharmacokinetic mechanism is the basis for several interaction-related restrictions and prohibitions.

Interaction-Related Restrictions and Classifications

Classification Examples of Interacting Substances
Contraindicated Combinations Simvastatin, Lovastatin, Terfenadine, Pimozide, Cisapride, Ergotamine, Dihydroergotamine
Clinically Significant Warfarin, Digoxin, Carbamazepine, Triazolam, Cyclosporine, Theophylline

Co-administration with Statins (like Simvastatin or Lovastatin) is contraindicated because CYP3A4 inhibition increases statin exposure, raising the risk of myopathy and rhabdomyolysis. Combinations with other agents, such as Pimozide, are also strictly contraindicated due to the potential for fatal cardiac arrhythmias and QT interval prolongation. Ergotamine and related alkaloids are prohibited due to the risk of acute ergot toxicity.

Exposure and Administration Constraints

Erythromycin may increase the serum concentration of drugs metabolized by CYP3A4, including Digoxin and oral anticoagulants like Warfarin, necessitating monitoring. Conversely, co-administration with potent CYP3A4 inducers, such as Rifampicin or the herbal product St John's Wort, can decrease erythromycin serum concentrations, requiring mandatory temporal separation. For optimal absorption, certain non-delayed-release Pantogram formulations must be administered in the fasting state. Caution is noted in patients with impaired hepatic function due to the drug’s primary reliance on the liver for excretion.

Mechanism of Action

How Pantogram Works

The pharmacodynamic action of Pantogram (Erythromycin) is defined by its targeted molecular interaction with key biological processes in both the microorganism and the human host.

Blocking Microbial Protein Assembly

The primary action is a reversible inhibition of the bacterial proliferation process. The molecule targets the 50 S ribosomal subunit, a key enzymatic complex in the microorganism's cytoplasm. By binding to this specific site, Pantogram physically obstructs the process of peptide chain elongation, thereby halting the synthesis of essential structural and functional proteins. This molecular cascade leads directly to the resulting physiological consequence of arresting microbial replication and proliferation (bacteriostasis).

Modulating Gastrointestinal Contractility

The drug also exerts a separate effect by acting as an agonist on the Motilin Receptor (MTR) located on the smooth muscle of the digestive tract. Activation of this receptor initiates an intracellular signaling cascade that increases smooth muscle tone and contractility. This mechanism influences gastrointestinal motility, resulting in the physiological consequence of enhanced movement and propulsion within the gut.

Mechanistic Constraints by Microbial Evasion

The drug's mechanism is constrained by bacterial counter-mechanisms. Strains can counter the drug's action by modifying the ribosomal target site to prevent binding, or by activating specialized efflux pumps that actively expel the drug molecule. These constraints impose boundaries on the drug's core mechanism, leading to a reduced functional expression of the inhibitory mechanism against microbial growth.

Dosage and Administration Information

How to Use Pantogram

Pantogram is primarily used via the oral route as a tablet, capsule, or suspension, though the active substance is also administered intravenously in specific clinical settings.

Standard Dosage and Administration Timing

The standard adult oral dosing regimen is typically 250 mg every six hours (q6h) or 500 mg every twelve hours (q12h), administered in divided doses. For severe infections, the daily dose may be increased up to a maximum of 4 grams (4000 mg). However, the standard schedule restricts twice-daily dosing when the total daily dose exceeds 1 gram.

The proper use of some forms, such as the base or stearate versions, requires consideration of meal timing. For optimal absorption, these forms are generally administered in a fasting state, such as at least 30 minutes before or 2 hours after a meal.

Procedural Constraints and Course Duration

To maintain the drug's integrity, delayed-release tablets and capsules must be swallowed whole and must not be chewed, crushed, or split. Liquid suspensions must be shaken well before measurement.

The duration of treatment is standardized and depends on the specific use pattern. For common infections, a course of at least 10 days is often required, while for certain other conditions, the duration may be shorter, such as 7 days, or continuous for long-term prophylaxis. For specific populations, the maximum adult dose typically does not exceed 1.5 grams per day for patients with severe renal impairment. In the event of a missed dose, the standard practice is to not take a double dose but rather to skip the missed dose if the time for the next scheduled dose is near.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Monotherapy Studies

Research efforts have focused on evaluating this approach for various pain conditions. Studies have focused on researching the pain intensity and frequency observed in participants. Findings from several studies have been published regarding its use for severe chronic pain.

Mechanism of Action Research

Research has explored the molecular changes associated with its use. Research has investigated the timing of observed responses in acute symptom studies.

Combined Treatment Investigations

Studies have documented the response profile of combined treatment in various populations. Studies have also evaluated the outcomes in populations with a history of heart conditions. Research is underway to assess its role in long-term management.

Special Population Findings

Studies have explored the observed effects across the age groups examined. The available evidence remains limited regarding its use during pregnancy or for patients with liver impairment. Research has not yet clarified the full range of required study parameters for these groups, and research has not yet clearly established the effects on these populations.

Key Studies & References

  1. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain
  2. Effectiveness of Outpatient Chronic Pain Management for Middle-Aged Patients by Internet Hospitals: Retrospective Cohort Study
  3. State of the Art in Hepatic Dysfunction in Pregnancy (Context for 'Pregnancy/Liver Impairment' and Special Populations)

Frequently Asked Questions (FAQ)

Common questions about Pantogram (FAQ)

Q: What conditions are officially approved for treatment with Pantogram?

A: Official documents from regulatory bodies describe Pantogram’s approved uses for various types of bacterial conditions. These uses generally include certain respiratory, skin, and urogenital infections. The drug is also approved for treating conditions such as intestinal amebiasis and pertussis, and as a measure for prophylaxis in certain situations.

Q: How is Pantogram chemically different from other medicines in the same class?

A: Pantogram is a first-generation macrolide. Regulatory research indicates that newer macrolide antibiotics derived from Pantogram are chemically more stable. Due to this difference, regulatory observations state these newer drugs may present a different tolerability profile.

Q: How frequently do people experience a specific side effect, such as dizziness or headache?

A: The most common side effects of Pantogram are related to the gastrointestinal system, such as nausea and diarrhea, and these occur in more than 1 in 100 people. Official safety reports classify a severe feeling of dizziness or other serious adverse effects as rare, meaning they happen in less than 1 in 1,000 people.

Q: Can Pantogram be associated with changes in mood or sleep patterns?

A: Regulatory sources have documented that rare, serious side effects can involve the central nervous system. These documented effects include symptoms such as hallucinations (seeing or hearing things that are not actually there).

Q: Does Pantogram interact with common over-the-counter pain relievers?

A: Official drug interaction checkers, which rely on FDA data, indicate that Pantogram does not have a known interaction with a common over-the-counter pain reliever like acetaminophen. This information is based on general regulatory data.

Q: Is it safe to consume alcohol while taking Pantogram?

A: Official regulatory advice for the oral form of Pantogram suggests patients avoid consuming alcohol. This is based on regulatory information regarding optimal drug absorption and the potential for side effects.

Q: How long does Pantogram generally remain in the body after the final dose?

A: Research on the drug’s elimination process, known as pharmacokinetics, indicates that Pantogram has a short biological half-life. The half-life in the bloodstream is approximately 2 hours for individuals who have normal kidney function.

Q: Where can a patient find reliable, authoritative studies or reports about Pantogram?

A: Reliable, detailed regulatory information is available directly from official US government sources. This data includes the FDA drug label information and the DailyMed records maintained by the National Institutes of Health (NIH).

Q: Are there any restrictions on non-prescription cough or cold medicines when taking Pantogram?

A: Regulatory documents caution that Pantogram interacts with certain substances often found in non-prescription cold medicines, such as specific antihistamines, due to the potential for serious cardiac risk.

Q: What are the described symptoms associated with an accidental overdose of Pantogram?

A: According to official safety data, symptoms reported in cases of overdose typically involve the gastrointestinal system. These symptoms may include severe diarrhea, nausea, stomach cramps, and vomiting.

Q: What official government resources provide the most comprehensive information on the safety of Pantogram?

A: The most comprehensive and detailed safety profile for the drug is available in the official FDA Prescribing Information. This document, alongside the detailed records on DailyMed, serves as a key source of regulatory safety information.

Q: What is the significance or purpose of the specific color or shape of the Pantogram tablets?

A: The specific physical characteristics of a tablet are not just for appearance. Official data states that features like the color, shape, and imprint mark serve as essential markers to identify the specific drug product and its strength.

Q: How is the patient’s response to Pantogram generally monitored by healthcare providers?

A: Official clinical guidance specifies that for patients being treated for certain infections, close monitoring is generally advised. This process allows the healthcare provider to assess the patient’s response to the medicine during the course of treatment.

Q: What official information is available regarding the potential for rare side effects?

A: Official adverse reaction reports categorize the most serious side effects as rare. These rare events are those that typically occur in less than 1 in 1,000 people who use the medication.

Q: Are there specific types of food or drink that officially interact with Pantogram?

A: Regulatory interaction information specifically notes that certain foods may affect the drug's concentration. For example, grapefruit and grapefruit juice may potentially increase the concentration of Pantogram in the body.

Q: How long does it typically take for Pantogram to start producing its intended effects?

A: Studies used in clinical guidance have documented that for some infections, symptomatic improvement has been observed to be evident within three days of starting therapy.

Q: Is Pantogram considered appropriate for use in older adults?

A: The official Summary of Product Characteristics (SmPC) for the drug contains information specific to different populations. This document indicates that no special dosage recommendations are provided for use in the elderly population.

Q: Is Pantogram intended to be used as a pain reliever or just for its other main purpose?

A: The designated primary therapeutic role of Pantogram is as an anti-infective agent to combat bacterial infections. However, the drug also has a separate mechanism of action that modulates gastrointestinal contractility.

Q: Why might a doctor prescribe Pantogram for one patient and a similar drug for another?

A: Official research and review articles highlight that newer macrolide antibiotics were developed to offer specific differences. These newer versions are noted to be more chemically stable and may present a different profile of activity against some microorganisms.

Q: Is it considered normal to feel slightly nauseous during the first few days of taking Pantogram?

A: According to regulatory documentation, nausea and other gastrointestinal disturbances are the most commonly reported side effects of Pantogram. These effects are often noted to be dose-related.

How should Pantogram be stored and disposed of?

How to Store and Dispose of Pantogram (Erythromycin)

The official storage requirements for Pantogram (Erythromycin) ensure product stability and safety. Solid forms, such as tablets and dry granules, must be stored at room temperature (typically below 30 C) and protected from light and excess moisture. Do not freeze any formulation.

Stability and Child Safety

The stability of the liquid suspension is formulation-dependent: refrigerated suspensions must be discarded after 10 days, while some room-temperature suspensions are stable for 35 days. All forms must be kept in the original, tightly closed container and stored out of the sight and reach of children.

Disposal Requirements

Unused or expired medication must not be flushed down the toilet or poured into a drain. The preferred disposal method is through an official drug take-back program. If unavailable, the medication should be mixed with an undesirable substance (e.g., dirt) and sealed in a plastic bag before discarding in household trash, according to federal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pantogram found in:

A-Z Index: